Ayala Pharmaceuticals focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers which are identified as having an aberrant activation of the Notch pathway. Such activation has long been implicated in multiple solid tumor and blood-related cancers and has often been associated with more aggressive cancers. In January 2023, Ayala Pharmaceuticals completed a merger with Advaxis, Inc., a public biotech company (ADXS).